Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talabostat + pemetrexed
- Development stage
- Unknown
- Lead developer
- BioXcel Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Talabostat + pemetrexed is a combination therapy of two small molecules: **talabostat** (PT-100), an oral dipeptidyl peptidase (DPP) inhibitor targeting DPP4 and DPP8/9, and **pemetrexed**, a multi-targeted antifolate chemotherapy agent. Talabostat's mechanism aims to enhance anti-tumor immune responses and potentially synergize with chemotherapy. The combination was developed primarily for the treatment of non-small cell lung cancer (NSCLC) after progression following platinum-based chemotherapy. Clinical trials reached phase 3 but did not result in an approval. The drugs are not known to have unique combination-therapy branding. Talabostat was developed by Point Therapeutics, while pemetrexed (brand: Alimta) is a product of Eli Lilly.
- Brand names
- Alimta (for pemetrexed)
- Other names
- talabostat mesylatePT-100PT100PT 100pemetrexed disodiumLY231514LY-231514LY 231514
02
Targets
DPP9 (Dipeptidyl Peptidase 9)TS (Thymidylate synthase)DPP8 (Dipeptidyl peptidase 8)DHFR (Dihydrofolate reductase)GART (GAR transformylase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)
Beyond the preview
Go deeper on talabostat + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talabostat + pemetrexed.